Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer
Vergote, Ignace × Chekerov, Radoslav Amant, Frédéric Harter, Philipp Casado, Antonio Emerich, Janusz Bauknecht, Thomas Mansouri, Kambiz Myrand, Scott P Nguyen, Tuan S Shi, Peipei Sehouli, Jalid #
Grune & Stratton
Journal of Clinical Oncology vol:31 issue:25 pages:3127-32
Enzastaurin is an oral serine/threonine kinase inhibitor antitumor agent. Our phase II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed advanced ovarian cancer.